Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten in Pediatric Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06412666Phase 3Active, not recruiting
- Sponsor
- Cytokinetics
- Start
- May 2024
- Primary completion
- Jan 2030
- Countries
- 6
01
Overview
A Phase 3 trial of aficamten in hypertrophic cardiomyopathy (HCM), sponsored by Cytokinetics. Started May 2024; status: active, not recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06412666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412666.